In addition to our previous work which identified PPARβ/δ as a therapeutic target for the metabolic syndrome9, PPARβ/δ activation and its key role in intestinal immune modulation may also prove effective for the management of T1D. Here, PPARD is linked to type 1 diabetes mellitus.